103 related articles for article (PubMed ID: 14515265)
41. Histologic aspects of concomitant resistance induced by nonimmunogenic murine tumors.
Meiss RP; Bonfil RD; Ruggiero RA; Pasqualini CD
J Natl Cancer Inst; 1986 Jun; 76(6):1163-75. PubMed ID: 3458952
[TBL] [Abstract][Full Text] [Related]
42. Extracellular matrix interacts with soluble CD95L: retention and enhancement of cytotoxicity.
Aoki K; Kurooka M; Chen JJ; Petryniak J; Nabel EG; Nabel GJ
Nat Immunol; 2001 Apr; 2(4):333-7. PubMed ID: 11276204
[TBL] [Abstract][Full Text] [Related]
43. Abrogation of tumor rejection by trypan blue.
Kreider JW; Bartlett GL; DeFreitas E
Cancer Res; 1978 Apr; 38(4):1036-40. PubMed ID: 205342
[TBL] [Abstract][Full Text] [Related]
44. Promotion of syngeneic intraocular tumor growth in mice by anterior chamber-associated immune deviation.
Niederkorn JY; Streilein JW; Kripke ML
J Natl Cancer Inst; 1983 Jul; 71(1):193-9. PubMed ID: 6575203
[TBL] [Abstract][Full Text] [Related]
45. Serum Ia levels during tumor growth in mice and humans.
Sandrin MS; Henning MM; Vaughan HA; McKenzie IF; Parish CR
J Natl Cancer Inst; 1981 Feb; 66(2):279-83. PubMed ID: 6935478
[TBL] [Abstract][Full Text] [Related]
46. Antitumor effect of locally produced CD95 ligand.
Seino K; Kayagaki N; Okumura K; Yagita H
Nat Med; 1997 Feb; 3(2):165-70. PubMed ID: 9018234
[TBL] [Abstract][Full Text] [Related]
47. Inhibition of the alloantibody response by CD95 ligand.
Arai H; Chan SY; Bishop DK; Nabel GJ
Nat Med; 1997 Aug; 3(8):843-8. PubMed ID: 9256273
[TBL] [Abstract][Full Text] [Related]
48. CD95 (Fas/APO-1)/CD95L in the gastrointestinal tract: fictions and facts.
Sträter J; Möller P
Virchows Arch; 2003 Mar; 442(3):218-25. PubMed ID: 12647210
[TBL] [Abstract][Full Text] [Related]
49. Tumor expression of Fas ligand (CD95L) and the consequences.
Walker PR; Saas P; Dietrich PY
Curr Opin Immunol; 1998 Oct; 10(5):564-72. PubMed ID: 9794830
[TBL] [Abstract][Full Text] [Related]
50. Transgenic expression of CD95 ligand on islet beta cells induces a granulocytic infiltration but does not confer immune privilege upon islet allografts.
Allison J; Georgiou HM; Strasser A; Vaux DL
Proc Natl Acad Sci U S A; 1997 Apr; 94(8):3943-7. PubMed ID: 9108084
[TBL] [Abstract][Full Text] [Related]
51. Down-regulation of human alloimmune responses by genetically engineered expression of CD95 ligand on stimulatory and target cells.
Dulat HJ; von Grumbkow C; Baars W; Schröder N; Wonigeit K; Schwinzer R
Eur J Immunol; 2001 Jul; 31(7):2217-26. PubMed ID: 11449376
[TBL] [Abstract][Full Text] [Related]
52. Can expression of CD95 (Fas/APO-1) ligand on grafts or tumor cells prevent their rejection?
Allison J; Seino K; Yagita H
Springer Semin Immunopathol; 1998; 19(3):311-22. PubMed ID: 9540159
[No Abstract] [Full Text] [Related]
53. Slowly getting a clue on CD95 ligand biology.
Linkermann A; Qian J; Janssen O
Biochem Pharmacol; 2003 Oct; 66(8):1417-26. PubMed ID: 14555216
[TBL] [Abstract][Full Text] [Related]
54. Tumor rejection by local interferon gamma induction in established tumors is associated with blood vessel destruction and necrosis.
Briesemeister D; Sommermeyer D; Loddenkemper C; Loew R; Uckert W; Blankenstein T; Kammertoens T
Int J Cancer; 2011 Jan; 128(2):371-8. PubMed ID: 20333679
[TBL] [Abstract][Full Text] [Related]
55. Contribution of CD95 ligand-induced neutrophil infiltration to the bystander effect in p53 gene therapy for human cancer.
Waku T; Fujiwara T; Shao J; Itoshima T; Murakami T; Kataoka M; Gomi S; Roth JA; Tanaka N
J Immunol; 2000 Nov; 165(10):5884-90. PubMed ID: 11067949
[TBL] [Abstract][Full Text] [Related]
56. The membrane-bound but not the soluble form of human Fas ligand is responsible for its inflammatory activity.
Shudo K; Kinoshita K; Imamura R; Fan H; Hasumoto K; Tanaka M; Nagata S; Suda T
Eur J Immunol; 2001 Aug; 31(8):2504-11. PubMed ID: 11500835
[TBL] [Abstract][Full Text] [Related]
57. Tumor counterattack--concept and reality.
Igney FH; Behrens CK; Krammer PH
Eur J Immunol; 2000 Mar; 30(3):725-31. PubMed ID: 10741386
[No Abstract] [Full Text] [Related]
58. [Immunologic assessment and acoustic "stressing situation" in an experimental system BALB/c mice, the Tsc-3T3 tumor].
Favre R; Grallan B; Verrier C; Serafino X; Carcassonne Y
C R Seances Acad Sci III; 1982 Jan; 294(3):159-64. PubMed ID: 6282400
[TBL] [Abstract][Full Text] [Related]
59. Role of Fas ligand expression in promoting escape from immune rejection in a spontaneous tumor model.
Céfai D; Favre L; Wattendorf E; Marti A; Jaggi R; Gimmi CD
Int J Cancer; 2001 Feb; 91(4):529-37. PubMed ID: 11251977
[TBL] [Abstract][Full Text] [Related]
60. Effect of tumors on the concentration of leucogenenol in the serum of mice.
Rice FA; Oresajo C; Heath JR; Breyere EJ; McCurdy JD
Cancer Res; 1981 Dec; 41(12 Pt 1):4976-80. PubMed ID: 7306998
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
